Pritack 150 mg (Tablet)
Unit Price: ৳ 2.50
Medicine Details
| Category | Details |
|---|---|
| Generic | Ranitidine hydrochloride |
| Company | Prime pharmaceuticals ltd |
Indications
- Treatment of active duodenal ulcer
- Benign gastric ulcer
- Treatment & prevention of ulcer associated with non-steroidal anti-inflammatory agent
- Post operative stress ulcer
- Zollinger-Ellison Syndrome
- Gastroesophageal reflux disease (GERD)
- Gastro-intestinal haemorrhage from stress ulcer in seriously ill patient
- Recurrent haemorrhage in patients with bleeding peptic ulcer
- Before general anesthesia in patient considered to be at risk of acid aspiration particularly obstetric patients
Pharmacology
- Competitively blocks histamine at H2-receptors of the gastric parietal cells
- Inhibits gastric acid secretion
- Does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin
Dosage & Administration
- Usual dosage is 150 mg twice daily taken in the morning and evening for 4 to 8 weeks
- 300 mg as a single daily dose at night for 4 to 8 weeks
- Dosage for reflux oesophagitis is 150 mg twice daily or 300 mg at bedtime for up to 8 weeks
- Dosage for Zollinger Ellison syndrome is 150 mg 3 times daily
- Episodic dyspepsia dosage is 150 mg twice daily or 300 mg at bedtime for up to 6 weeks
Interaction
- Delayed absorption and increased peak serum concentration with propantheline bromide
- Minimally inhibits hepatic metabolism of certain drugs
Contraindications
- Patients hypersensitive to Ranitidine
Side Effects
- Altered bowel habit
- Dizziness
- Rash
- Tiredness
- Reversible confusional states
- Headache
- Decreased blood counts
- Muscle or joint pain
Pregnancy & Lactation
- Ranitidine crosses the placenta
- No evidence of impaired fertility or harm to the foetus
- Caution should be exercised when the drug is administered to a nursing mother
Precautions & Warnings
- Should be given in reduced dosage to patients with impaired renal and hepatic function
Use in Special Populations
- Ulcer healing rates have been found similar in patients age 65 and over with those in younger patients
- No difference in the incidence of adverse effects in elderly patients
Overdose Effects
- No particular problems are expected following overdosage with the drug
- Symptomatic and supportive therapy should be given as appropriate
Therapeutic Class
- H2 receptor antagonist
Reconstitution
- Instructions for reconstitution for slow IV injection and infusion
- Special instructions for patients with Zollinger-Ellison syndrome or other hypersecretory conditions
Storage Conditions
- Store in a cool and dry place
- Protect from light